Prematurely Ended Clinical Trials Produce Misleading Results

A new study has found that <"http://www.yourlawyer.com/practice_areas/defective_drugs">clinical trials that are ended early often produce misleading or exaggerated positive results. The study, published in the current issue of the Journal of the American Medical Association, was conducted by researchers at the Mayo Clinic and supported by the Medical Research Council of the United Kingdom.

Victor Montori, M.D., a Mayo Clinic endocrinologist and corresponding author of the study, said almost everyone involved benefits from a trial ending early — doctors, researchers, funding sources, pharmaceutical firms, scientific journals, even reporters. Everyone that is, except the patient, who may end up receiving a therapy on the basis of misleading information about its benefits.

To reach these conclusions, the researchers examined 63 medical questions regarding 91 truncated trials and compared them to 424 comparable trials that were not stopped early. Results showed that the studies that were stopped — especially smaller trials of a few hundred participants — had exaggerated or misleading treatment effects. The study found that those misleading findings are often compounded downstream because researchers are less likely to return to the topic after what is perceived as a significant successful finding.

According to a press release detailing the study, the clinical trials included were ended early because of a convincing — and usually large — apparent difference between an experimental treatment and an existing standard therapy. The studies were ended so participants taking a placebo or less effective medications could also take the studied drug. It usually also allows physicians to prescribe the therapy sooner because it will reach the market earlier.

“Our research shows that in most cases early stopping of clinical trials resulted in misleading estimates of treatment effects. These misleading estimates are likely to result in misguided decisions about the trade-off between risks and benefits of a therapy.” Dr. Montori said in the release. “On average, treatments with no effect would show a reduction in relative risk of almost 30 percent in stopped early trials. Treatments with a true relative risk reduction of 20 percent would show a reduction of over 40 percent.”

The authors of the study recommend that researchers use restraint and truncate clinical trials only near the end of a study and then only with “a very good reason.” Otherwise, says Dr. Montori, patients and physicians will be making treatment choices based on inaccurate information, or worse, opting for one treatment when another may be more appropriate.

This entry was posted in Defective Medical Devices, Pharmaceuticals. Bookmark the permalink.


© 2005-2016 Parker Waichman LLP ®. All Rights Reserved.